BERKELEY, CA & VANCOUVER, BC – Thursday February 11th 2016: BriaCell Therapeutics Corp (OTCQB:BCTXF) (TSXV: BCT) (“BriaCell”, the “Company”, or “BCT”), an immuno-oncology focused biotechnology company with a proprietary vaccine technology, BriaVaxTM, is pleased to announce that it has hired Mr. Gadi Levin, CPA, MBA, as the Company’s new CFO. Mr. Levin is a highly experienced accountant & businessman, who has been involved in a number of successful ventures. Mr. Levin has experience on both sides of the table, having prior served as a CFO in addition to having been VP Finance for a large hedge fund. This appointment takes place as the Company continues to engage in discussions with institutional investors and potential pharma collaborators.
Concurrently, the Company announces the resignation of Mr. Matthew Wright, and wishes to thank Mr. Wright for all of his services through BriaCell’s recent period of growth, including the Company’s go-public.
AGM RESULTS
BriaCell reports that it’s AGM held on January 25th, 2016, successfully approved the Company’s nominees for directors. Shareholders also voted to approve the appointment of MNP LLP as the Company’s auditors. Additionally, shareholders approved the Company’s stock option plan. All votes obtained in excess of 99% approval.
ABOUT BRIACELL
BriaCell is an immuno-oncology focused biotechnology company that has demonstrated unique and unprecedented clinical results, and is intent on building upon these results to further advance BriaVaxTM through the FDA clinical trials in order to help cancer patients with no other options. The results of two FDA Phase I clinical trials have been highly promising in terms of both safety and efficacy in patients with advanced, stage-IV breast cancer.
Most uniquely, BriaCell has achieved these results in patients who had prior failed all other available therapies including various kinds of chemotherapy. In some cases, the lifespan was five times longer expected. The results were targeted, with little to no side effects, and were achieved rapidly, with marked regression occurring within 6 weeks.
The team at BriaCell is working towards aggressively advancing BriaVaxTM into the next Phase-IIa clinical trial which will include up to 24 additional late-stage cancer patients. For further information, please refer to Company’s website: www.briacell.com
BriaCell Contact:
Dr. Joseph Wagner
1-888-485-6340
Cautionary Note on Forward Looking Statements
The TSX Venture Exchange Inc. has in no way passed upon the merits of the Company has neither approved nor disapproved the contents of this press release. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors – including the availability of funds, the results of financing efforts, the results of exploration activities — that could cause actual results to differ materially from the Company’s expectations are disclosed in the Company’s documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. This press release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities described herein in the United States or elsewhere. These securities have not been, and will not be, registered in the United States Securities Act of 1933, as amended, or any state securities laws, and may not be offered or sold in the United States or to U.S. persons unless registered or exempt therefrom.